Role of CPX-351 in Acute Myeloid Leukemia

CPX-351 versus intensive induction chemo in pts with tAML or AML with myelodysplasia-related changesПодробнее

The promise of CPX-351 in secondary AMLПодробнее

Safety run-in of a Phase II trial of CPX-351 plus pomalidomide in AML with MDS-related changesПодробнее

Common Sense Oncology Journal Club: Acute Myeloid Leukemia (AML)Подробнее

Low bone marrow cellularity predicts hematologic AEs to CPX-351 in AMLПодробнее

CPX-351 plus venetoclax in patients with newly-diagnosed high-risk AMLПодробнее

Acute Myeloid Leukemia Beyond FLT3 and IDH: The Role of Non-Targetable Driver MutationsПодробнее

The real-world safety and efficacy of CPX-351 in patients with AMLПодробнее

A real-world study of the optimal duration of CPX-351 treatment in patients with AMLПодробнее

Choosing between CPX-351 and FLAG-Ida in newly diagnosed and R/R AMLПодробнее

V-FAST subgroup analysis: CPX-351 plus midostaurin for newly diagnosed FLT3-mutated AMLПодробнее

AML19: FLAG-Ida vs CPX-351 in patients with AML with adverse risk cytogeneticsПодробнее

Cardiotoxicity of CPX-351 vs 7+3 chemotherapy in patients with untreated high-risk AMLПодробнее

CPX-351 with venetoclax in R/R AML: results of a Phase Ib studyПодробнее

The benefit of CPX-351 over 7+3 in patients with sAML by baseline bone marrow percentageПодробнее

CPX-351 and gemtuzumab ozogamicin in R/R AML and MDSПодробнее

Do Baseline Blast Percentages Impact Survival Outcomes with CPX-351 in AML?Подробнее

Long-term real-world experience of CPX-351 in patients with t-AML and MRC-AMLПодробнее

Evaluating the optimal duration of CPX-351 treatment & best timing for alloSCT consolidation in AMLПодробнее